Overview Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis Status: Completed Trial end date: 2011-11-01 Target enrollment: Participant gender: Summary This is an observational study to assess the tolerability of Rebif treatment in Korean multiple sclerosis (MS) subjects. Details Lead Sponsor: Merck KGaAMerck KGaA, Darmstadt, GermanyTreatments: Interferon beta-1aInterferon-betaInterferons